Fructose and follistatin potentiate acute MASLD during complete hepatic insulin resistance

Rongya Tao1, Oliver Stöhr1, Ozlem Tok2

  • 1Division of Endocrinology Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.

Nature Communications
|November 23, 2025
PubMed

Insights

Metabolic-associated steatotic liver disease (MASLD) can develop without insulin resistance, driven by fructose metabolism. Follistatin (FST) promotes MASLD by increasing hepatic fat accumulation, even without insulin signaling.

Area of Science:

  • Hepatology
  • Metabolic Syndrome
  • Endocrinology

Background:

  • Metabolic-associated steatotic liver disease (MASLD) and steatohepatitis (MASH) are linked to hepatic insulin resistance (IR) and type 2 diabetes (T2D).
  • Hepatic lipogenesis stimulated by insulin is traditionally considered crucial for MASLD development.

Purpose of the Study:

  • To investigate the role of fructose metabolism and insulin signaling in MASLD pathogenesis.
  • To challenge the established notion that insulin-stimulated hepatic lipogenesis is essential for MASLD development.

Main Methods:

  • Utilized male liver-direct knockout (LDKO) mice lacking hepatic insulin receptor substrates.
  • Administered fructose-enriched diets (MASH diet/GAN or high-fructose diet).
  • Traced hepatic triacylglyceride synthesis using [U-13C]fructose and assessed the impact of Follistatin (Fst) manipulation on MASLD development.

Main Results:

  • LDKO mice developed acute MASLD when fed fructose-enriched diets, despite complete hepatic IR.
  • Fructose enhanced hepatic re-esterification of circulating fatty acids in LDKO mice.
  • Inactivating hepatic Fst prevented MASLD in LDKO mice, while Fst overexpression accelerated MASLD/MASH in wild-type mice.
  • Elevated serum FST levels correlated with increased adipose IR and hepatic triacylglyceride accumulation in human study participants.

Conclusions:

  • Insulin-stimulated hepatic lipogenesis is not essential for MASLD development.
  • Fructose metabolism plays a critical role in promoting MASLD, particularly in the context of hepatic insulin resistance.
  • Follistatin (FST) acts as a key mediator in MASLD pathogenesis by potentiating hepatic fat accumulation.

Related Concept Videos

Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
567
Insulin: The Receptor and Signaling Pathways01:28

Insulin: The Receptor and Signaling Pathways

Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
2.7K
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
509
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
824
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion01:27

Glucose Homeostasis: Pancreatic Islets and Insulin Secretion

The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
2.1K
Hormones Regulating Blood Glucose01:16

Hormones Regulating Blood Glucose

Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
6.4K